在保健品行业蓬勃发展的当下，跨境电商已成为品牌拓展全球市场的重要渠道。然而，面对复杂的国际 法规、供应链挑战及生产成本压力，越来越多的保健品企业选择代加工（OEM/ODM）模式切入跨境电 商赛道。为何代加工能成为行业主流选择？本文从专业角度解析其核心优势。 灵活应对市场动态 跨境电商市场变化迅速，消费者需求呈个性化、碎片化趋势。代加工模式赋予品牌方高度灵活性：可根 据销售数据快速调整订单量，避免库存积压；可灵活更换包装设计或配方微调，适配不同区域消费偏 好。代工厂的敏捷生产体系支持"小批量、多批次"订单，帮助品牌降低试错成本，精准捕捉市场机会。 跨境电商需应对多国市场差异化需求，自主研发与生产将面临高昂的设备投入、人力成本及时间成本。 代加工模式通过专业化分工，将生产环节交由经验丰富的工厂完成，品牌方可聚焦市场策略与销售渠 道。代工厂具备成熟的生产线、规模化采购优势及标准化流程，能有效降低单品成本，缩短产品从研发 到上市的周期，提升资金周转效率。 合规与质量的刚性保障 保健品跨境销售需遵循各国严格的食品安全法规（如FDA、CE、欧盟新规等），合规门槛极高。专业 代加工企业通常具备GMP认证、ISO体系等资质， ...

（编辑 姚尧） 证券日报网讯 金达威9月15日在互动平台回答投资者提问时表示，关于NMN，公司会积极与监管机构 进行沟通，跟进国内相关政策法规的最新进展。截至目前，国家卫健委尚未正式公开披露其具体委托进 行NMN作为食品添加剂或保健品原料准入评审的国内科研机构或生产单位名单。公司将继续与国内相 关的行业机构、科研单位保持技术交流与合作，共同推动NMN领域的科学研究。 ...

Core Viewpoint - The company has faced continuous pressure on its performance and stock price, with investors questioning the feasibility of its ambitious sales targets in light of recent declines in revenue and profit [1] Group 1: Financial Performance - The company has averaged annual sales of approximately 700 million yuan in recent years, with a significant drop in revenue and net profit in the first half of 2023, down 16.51% and 33.99% respectively [1] - The company set a vision to achieve 10 billion yuan in revenue by 2035, but has struggled since 2019, with 2022 revenue peaking at 829 million yuan [1] Group 2: Marketing Strategy - The company has faced criticism for its conservative marketing strategy, which is believed to have negatively impacted product market performance [2] - In response, the company has shifted its strategic focus to "marketing-driven enterprise" and is implementing marketing reforms, including enhancing offline channels and exploring new retail avenues [2] - The company has begun to engage in live-streaming sales, partnering with top live-streaming teams to boost online marketing efforts [2]

Core Viewpoint - Xianle Health's stock price has shown a year-to-date increase of 26.74%, indicating positive market performance despite a recent decline of 2.07% on September 12 [2][1]. Company Overview - Xianle Health Technology Co., Ltd. was established on August 16, 1993, and went public on September 25, 2019. The company is based in Shantou, Guangdong Province and specializes in the research, production, sales, and technical services of nutritional health products [2]. - The company's revenue composition includes soft capsules (46.38%), gummies (25.31%), tablets (9.26%), beverages (5.42%), hard capsules (5.31%), powders (4.45%), and other forms (3.22%) [2]. Financial Performance - For the first half of 2025, Xianle Health reported a revenue of 2.042 billion yuan, representing a year-on-year growth of 2.57%. The net profit attributable to shareholders was 161 million yuan, reflecting a growth of 4.30% compared to the previous year [2]. - Since its A-share listing, Xianle Health has distributed a total of 583 million yuan in dividends, with 415 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Xianle Health reached 12,100, an increase of 9.08% from the previous period. The average number of circulating shares per shareholder was 21,172, up by 19.00% [2]. - Notable institutional shareholders include招商产业精选股票A (holding 2.2 million shares) and东方红核心价值混合A (holding 1.8095 million shares), both of which are new entrants among the top ten circulating shareholders [3].

Core Insights - The report highlights a positive trend in the semiconductor industry, with significant growth in domestic AI computing chip manufacturers, indicating a robust market opportunity [14][16][18] - The media sector shows a notable recovery in profitability, with a significant increase in net profit compared to the previous year, suggesting a favorable investment environment [18][19] - The food and beverage sector has experienced a strong performance in August, with a notable increase in individual stock prices, indicating a potential investment opportunity [22][23][25] Domestic Market Performance - The Shanghai Composite Index closed at 3,875.31, with a daily increase of 1.65%, while the Shenzhen Component Index rose by 3.36% to 12,979.89 [3] - The average price-to-earnings ratio for the Shanghai Composite and ChiNext indices are 15.55 and 47.12, respectively, indicating a suitable environment for medium to long-term investments [9][10][12] Industry Analysis - The semiconductor industry saw a 23.84% increase in August, outperforming the Shanghai and Shenzhen indices, with integrated circuits rising by 31.47% [14] - The media sector's overall revenue reached 2,728.86 billion yuan in the first half of 2025, marking a 2.91% year-on-year increase, with net profit growth of 38.08% [18][19] - The food and beverage sector's stock performance improved significantly, with 83.59% of individual stocks rising in August, particularly in snacks and beverages [22][23] Investment Recommendations - The report suggests focusing on the semiconductor industry, particularly domestic AI computing chip manufacturers, as they are expected to gain market share [14][16] - In the media sector, the gaming sub-sector is highlighted for its strong fundamentals and growth potential, while the film and publishing sectors show mixed results [18][19] - The food and beverage sector is recommended for investment, particularly in white liquor, soft drinks, and snacks, due to their strong performance and recovery potential [22][25]

Investment Rating - The investment rating for the company is "Buy" [2][12]. Core Insights - The company has successfully transitioned from a brand operation model to a brand owner model, achieving significant growth in performance since 2024. The self-owned brand business has shown rapid growth, with revenues reaching 5.01 billion yuan in 2024, a year-on-year increase of 90.28%, and 6.03 billion yuan in the first half of 2025, a year-on-year increase of 242.42% [4][11][19]. Summary by Sections Company Overview - Founded in 2011, the company initially focused on brand operation. In late 2020, it launched its own home cleaning brand, Zhanjia, marking its transition to a brand owner. By July 2025, it had established a brand matrix centered around Zhanjia for home cleaning and Feicui & VitaOcean for health products [11][12]. Business Performance - The self-owned brand revenue accounted for 45.75% of total revenue in the first half of 2025, with Zhanjia generating 4.44 billion yuan (up 157.11% year-on-year) and Feicui generating 1.60 billion yuan [4][11][19]. The company expects revenues of 30 billion yuan, 42 billion yuan, and 54 billion yuan for 2025, 2026, and 2027, respectively, with corresponding growth rates of 70%, 40%, and 30% [12]. Zhanjia Brand - Zhanjia focuses on the home cleaning market, emphasizing "emotional fragrance" to create a mid-to-high-end brand. The brand launched its strategic flagship product, the Four Seasons Fragrance Laundry Liquid, in March 2024, which significantly boosted sales [11][44]. In 2024, Zhanjia's revenue reached 4.84 billion yuan, with a gross margin of 66.92% [4][11]. Feicui Brand - Feicui targets high-end female anti-aging products and has seen rapid growth since its launch in September 2024. The brand achieved 1.20 million yuan in revenue in 2024 and 1.6 billion yuan in the first half of 2025, with a gross margin of 86.81% [4][11][19]. The company has also launched VitaOcean, focusing on ruby oil, and aims to maximize the value of this ingredient through its brand matrix [11][12]. Market Trends - The home cleaning market in China is steadily growing, with e-commerce platforms being the primary source of information for consumers. The demand for home cleaning products is shifting from basic cleaning capabilities to longer-lasting fragrances and emotional value [29][36]. The health supplement industry also shows significant growth potential, particularly in areas like gut health and beauty [11][19]. Financial Projections - The company forecasts a compound annual growth rate (CAGR) of 36% for net profit from 2025 to 2027, which is higher than comparable companies in the A-share personal care sector. The target market capitalization is set at 154 billion yuan [12][19].

Core Insights - Vanpearl, a Canadian health food brand under Youquhui, achieved total sales exceeding 4 million yuan and sold over 8,000 bottles during the Singapore traceability event held from September 7 to 9 [1][2] - The ERGO-VITALIS gene capsule, Vanpearl's core product, features a patented formula designed to repair DNA and delay aging, enhancing cellular self-repair and metabolic efficiency [1] - The collaboration with "Molecular Lab" not only resulted in high traffic and conversion rates but also strengthened Vanpearl's brand influence in the premium health supplement market [1] Sales Performance - Total sales during the event surpassed 4 million yuan, with over 8,000 bottles sold [1][2] - The product ranked first on Douyin's health food sales chart during the live broadcast on September 7 [1][2] Product Innovation - The ERGO-VITALIS gene capsule incorporates cutting-edge research and innovative ingredients aimed at DNA repair and anti-aging [1] - The product is described as a "gene guardian," focusing on enhancing the stability of the DNA genome and improving cellular repair efficiency [1] Brand Strategy - Youquhui leverages its capabilities in supply chain management, brand operation, and cross-border e-commerce to connect its own brands with international research resources [1]

智通财经APP获悉，9月7日至9日，优趣汇(02177)旗下加拿大保健食品Vanpearl携手"大分子实验室"开启 新加坡溯源专场再传捷报，实现总销售额突破400万元，销售数量超过8000瓶(1)，并在7日首发场持续 霸榜抖音保健食品带货榜TOP1，直播间流量与转化表现超高(2)。 备注： Vanpearl作为优趣汇重点孵化的加拿大保健食品品牌，其核心产品ERGO - VITALIS™基因胶囊，凝聚了 前沿科研智慧与创新成分，产品蕴含着修复DNA延缓衰老的专利配方，它能精准激活细胞本源的生命 因子，有效替换受损DNA基因片段，同时全方位保护DNA基因组稳定，从根本上提升细胞自我修复效 率与代谢效率，实现细胞DNA基因层面的抗衰老效果，堪称 "基因守护者"。 此次Vanpearl与大分子合作的新加坡溯源专场，不仅实现了流量与转化的双高表现，也进一步巩固了其 在高端保健品市场的品牌影响力。优趣汇也凭借着在供应链、品牌运营与跨境电商领域的整合能力，持 续推动自有品牌与国际科研资源对接。 (1)以上销售及数量数据取自9月7号-9月9号，数据来源于飞瓜 (2)9月7号基因胶囊新加坡研学专场首发8点-9点持续霸榜保健食品 ...

Group 1 - Dematech won a 900 million yuan overseas smart logistics project from a well-known e-commerce giant in Latin America, focusing on intelligent logistics cross-belt sorting systems and related services [1] - Kang En Bei received approval for the registration of short-term financing bonds and medium-term notes, with a total registration amount of 1 billion yuan, valid for two years [1][2] - Zhi Xiang Jin Tai's GR1803 injection for systemic lupus erythematosus clinical trial has been approved by the National Medical Products Administration [2] Group 2 - Jin Da Wei's subsidiary received approval for a veterinary drug product, pyridone, valid from September 3, 2025, to September 2, 2030 [4] - Fu Li Wang's subsidiary plans to invest 500 million yuan in a high-end wire material project, focusing on high-strength prestressed steel strands for various applications [5] - He Li Biological's subsidiary's Class III medical device registration application has been accepted, focusing on natural bone repair materials [12] Group 3 - Lin Yang Energy won a 244 million yuan metering equipment project from Southern Power Grid, expected to positively impact its 2025 and 2026 performance [20] - Sanxia Water plans to absorb its wholly-owned subsidiary, Chongqing Changdian United Energy, with all assets and liabilities to be inherited by Sanxia Water [13] - Tian Cheng Technology canceled the use of 91 million yuan of raised funds for permanent working capital, ensuring no impact on the normal operation of investment projects [24] Group 4 - Baosteel received approval to publicly issue bonds totaling 20 billion yuan to professional investors, valid for 24 months [52] - Tian Kang Biological reported a 10.15% year-on-year increase in pig sales in August, with a total of 263,800 pigs sold [53] - Xinjiang Construction won multiple major projects totaling 4.506 billion yuan, including a 2.4 billion yuan photovoltaic hydrogen synthesis project [18]

Group 1 - The company has issued a total of 160 million new shares at a subscription price of HKD 0.097 per share, with 30 million shares allocated to Subscriber I, 20 million shares to Subscriber II, and 110 million shares to Subscriber III [1] Group 2 - The board has discussed diversifying its business, recognizing that pharmaceuticals and healthcare are core to the "Healthy China 2030" national strategy, benefiting from trends such as an aging population and increasing chronic diseases [2] - The company has a solid foundation in drug production and has shown stable performance in recent years, although international market expansion has faced significant challenges due to varying regulatory requirements [2] - The board sees greater potential in expanding healthcare business overseas, as it typically faces less stringent regulations and faster market entry, particularly in emerging markets with growing middle classes and rising healthcare spending [2] - The new healthcare business is expected to synergize with the company's existing manufacturing infrastructure and distribution network, leveraging the experience of board members in medical devices, diagnostic services, and healthcare investment management [2] - The company plans to strategically allocate approximately 70% of the net proceeds from the share issuance to the startup costs of the new business, including product development, operational expenses, marketing, and pilot projects, while the remaining 30% will be reserved for working capital [2] - This phased strategy aims to systematically establish the healthcare business while maintaining financial flexibility [2]